B A C K G R O U N D Description of the condition
Up to 10% of all births globally are preterm (born less than 37 weeks' gestational age) (March of Dimes 2012). Over one million babies die each year as a direct consequence of being born preterm (Lawn 2013) . Preterm birth can have significant effects on short-term morbidity and mortality, and also long-term health and disability. The short-term sequelae of preterm birth include respiratory distress syndrome (RDS), intraventricular haemorrhage (IVH), necrotising enterocolitis (NEC), retinopathy of prematurity, patent ductus arteriosus and sepsis (Haram 2003; Saigal 2008) . RDS develops as a consequence of immature lung development and is the major cause of early neonatal morbidity and mortality in preterm infants. Prematurity can also predispose to the development of chronic lung disease (bronchopulmonary dysplasia) which may be associated with impaired airway function into adult life (Doyle 2006; Saigal 2008) . In those infants who do survive there are increased risks of long-term neurodevelopmental disability (Saigal 2008) , including cerebral palsy, and intellectual, visual and hearing impairment (Anderson 2003; Doyle 2001; Farooqi 2006; Wood 2000) . Therefore prematurity and its associated sequelae has significant psychosocial and emotional effects on families caring for these infants (Saigal 2000; Singer 1999) . Being born preterm also increases the risk of developing non-communicable diseases such as diabetes and hypertension in later life (Hovi 2007) . The rates of preterm birth are increasing in almost all countries with reliable data (Blencowe 2012). The greatest burden of preterm birth occurs in Africa and Asia (Blencowe 2012) where the use of interventions to mitigate the effects of preterm birth varies substantially (Vogel 2014) . Reasons for preterm birth vary by geographical location. In high-income countries the numbers of provider-initiated preterm births has been rising (Blencowe 2012). In France and the United States, over 30% of all preterm births were medically indicated in 2000 (Blondel 2012; Davidoff 2006) . It is difficult to differentiate the cause of preterm birth in lowand middle-income countries due to the lack of population-based studies. However medically-indicated preterm births represent a much smaller proportion of all preterm births in low-and middleincome countries when compared with spontaneous preterm birth (Alhaj 2010; Nkyekyer 2006) . Overall, up to a third of all preterm births and up to half of very preterm births are provider-initiated (encompasses urgent, discretionary, iatrogenic and social) (Goldenberg 2008; Menon 2008; Steer 2005) . The main maternal/fetal indications for preterm delivery are maternal pre-eclampsia, antepartum haemorrhage, and chronic or acute fetal compromise, including fetal distress and severe intrauterine growth restriction (Ananth 2006) . The incidence of medically indicated preterm birth is likely to continue to rise due to increasing maternal disease, particularly in view of the world-wide epidemics of diabetes and obesity (Lawn 2013). The aetiology of spontaneous preterm birth is not completely understood but it is likely to be multifactorial (Lawn 2013) . In up to half of the cases the cause remains unknown (Menon 2008) . Up to half of spontaneous preterm births occur following preterm prelabour rupture of membranes (Goldenberg 2008) . Another important risk factor is multiple pregnancy, which is responsible for approximately 15% to 20% of all preterm births (Goldenberg 2008) . A large contributor to the increasing incidence of multiple pregnancies has been advancing maternal age and the use of assisted reproductive techniques (Felberbaum 2007) . Advancing maternal age has also been identified as an independent risk factor for spontaneous preterm birth (Goldenberg 2008). The incidence of preterm birth is not equally distributed across all gestational ages. Only 5% of preterm births occur at less than 28 weeks' gestation, approximately 15% at 28 to 31 weeks', 20% at 32 to 33 weeks ' and 60% to 70% at 34 to 36 weeks' gestation ( Goldenberg 2008) . However, these figures can also vary depending on geographical location. Recent data from Australia reported an overall incidence of preterm birth of 7.7%, of which 10% occurred at 20 to 27 weeks', 9% at 28 to 31 weeks and 81% at 32 to 36 weeks' gestation (Hilder 2014). Overall, the risks associated with prematurity are inversely related to gestational age (Saigal 2008) . Marked improvement in survival rates of preterm infants in recent decades, particularly those born very preterm, has been attributed to administration of antenatal corticosteroids, surfactant use, the use of assisted ventilation and changing attitudes towards intensive care (Doyle 1999; Roberts 2006; Rojas-Reyes 2012) . However survival rates vary significantly depending on where preterm infants are born. The improvement in mortality in high-income countries is most marked at extremes of gestation and in infants of extremely low birthweight (Saigal 2008 (Hook 1997; Maisels 1977; Morrison 1995) . Opinion is divided on the necessity of antenatal corticosteroids at term, as approximately only 5% of these babies will require admission for respiratory distress and serious morbidity is uncommon (Stutchfield 2005) . There is also some concern about the potential for longterm adverse effects of corticosteroid exposure in more mature fetuses (Aiken 2014; Steer 2005 
Description of the interventions
Antenatal corticosteroids are listed and recommended by the World Health Organization as a priority intervention in the prevention of RDS and mortality in preterm babies (PMNCH 2011; WHO 2015) . However, rates of antenatal corticosteroid use in low-and middle-income countries remain low (Vogel 2014), indicating that there is an opportunity to improve outcomes for preterm babies through administration of antenatal corticosteroids (Dalziel 2014 ). An analysis conducted for the Global Action Report on Preterm Birth indicated if universal coverage (95%) of antenatal corticosteroids was achieved across the 75 priority countries by 2015, 373,000 additional infant deaths could be averted per year compared to 2010 figures (March of Dimes 2012). However, caution has been advised in upscaling antenatal corticosteroid administration (Althabe 2014), particularly in low-income countries where access to other effective interventions may be limited, such as accurate dating of the pregnancy, and the provision of effective neonatal resuscitation (Lawn 2013) . A single course of antenatal corticosteroids has been identified as a highly effective and safe intervention for women at risk of preterm birth to reduce neonatal mortality and morbidity (Crowley 1990; Roberts 2006) . Their benefit was first described in the landmark trial conducted in New Zealand by Liggins and Howie in the late 1960s (Liggins 1972) . Subsequently more than 20 clinical trials conducted in high-and middle-income countries and a number of systematic reviews have confirmed the efficacy of antenatal corticosteroids in significantly reducing the risk of RDS, neonatal death, IVH, NEC and early sepsis (Crowley 1990; Roberts 2006) . Evidence suggests that in babies born more than seven days following antenatal corticosteroid treatment there is no reduction in the incidence of RDS compared to no antenatal corticosteroid treatment (Roberts 2006). Therefore repeat antenatal corticosteroids have been administered to women who remain at risk of preterm birth seven or more days after an initial course. Accumulating evidence has demonstrated that a repeat dose or doses of the synthetic corticosteroid, betamethasone is associated with a reduced risk of RDS and combined serious neonatal morbidity compared with a single course of antenatal corticosteroids (Crowther 2015). Uncertainty still exists around the effects of repeat antenatal corticosteroids of reduced birthweight and the long-term effects in both childhood and later life following repeat in utero exposure (Crowther 2015) . Reassuringly, long-term follow up of infants exposed to a single course of antenatal corticosteroids into early adulthood has not demonstrated any increased cardio-metabolic risk ( (Table 1; Table 2 ). Trial regimens of a single course of antenatal betamethasone have included administering a total dose of betamethasone between 12 mg to 48 mg in single or multiple doses, at varied time intervals between doses (immediate, eight hours, 12 hours and 24 hours between doses), compared to no antenatal corticosteroids (Table 1) . Trial regimens of a single course of dexamethasone have included administering a total dose of dexamethasone between 20 mg to 24 mg in multiple divided doses, at varied time intervals between doses (eight hours, 12 hours and 24 hours), compared to no antenatal corticosteroids (Table 2) . Trials have also compared administration of a repeat course or courses of antenatal corticosteroids compared to no repeat antenatal corticosteroids (Table 3) . Predominantly these trials have administered betamethasone as the repeat course(s) apart from one trial that used dexamethasone (administered intramuscularly) as a repeat course (n = 31 participants) (Garite 2009) due to the temporary unavailability of betamethasone. The trial regimens of repeat antenatal betamethasone compared with no repeat antenatal corticosteroids have included administering a total dose of betamethasone between 11.4 mg to 24 mg per repeat course, in a single or multiple dose regimen (24 hours apart between doses). The time interval between the administration of repeat courses and number of repeat courses varied between trials. Only one regimen of oral dexamethasone has been evaluated in a clinical trial (Egerman 1998; Regimen; four doses of 8 mg, 12 hours apart, total dose: 32 mg).
How the intervention might work
Glucocorticoids are known to have physiological and biochemical effects not only on the fetal lung, but in most fetal organ systems (Fowden 1998). They promote structural and functional maturation, preparing the fetus for life outside the womb. Synthetic corticosteroids promote a co-ordinated maturation response in fetal tissues similar to that occurring with the normal pre-partum surge in fetal corticosteroid production (Liggins 1994). The effects of glucocorticoids have been investigated extensively in animal models and the fetal lung (Ballard 2000) . Experimental studies in animals and human fetal lung explants have demonstrated that exposure of the preterm fetus to corticosteroids increases tissue and alveolar surfactant production, lung compliance, clearance of fluid from the lungs, maturation of parenchy-mal structure and reduced vascular permeability (Ballard 1995). These effects help to moderate some of the consequences of being born preterm with immature lung structure and function (Ballard 1995) . At a molecular level glucocorticoids primarily act by inducing gene transcription via the glucocorticoid receptor. This leads to increased concentration of various enzymes and proteins, including lung phospholipids and surfactant proteins (Ballard 1995) . The finding that glucocorticoid action is reversible following dissociation of the steroid from the receptor and the clinical observation that corticosteroid effectiveness appears to diminish over time, if the fetus remains in utero, has resulted in the administration of repeat steroids to women who remain at risk of preterm birth (Ballard 1995; Liggins 1972) . This was originally proposed by Liggins and Howie and has been supported further by experimental data showing that gene transcription can be repetitively induced (Ballard 1995; Ballard 1997; Willet 2001) . The available evidence from follow up of children exposed to repeat antenatal corticosteroids in utero compared to unexposed children has been reassuring, and has demonstrated no differences in mortality, neurosensory disability, measurements of growth, blood pressure or respiratory morbidity compared to no repeat exposure The pathophysiology underlying respiratory morbidity in infants born by elective caesarean section at term is thought to be different to that occurring after preterm birth (Brown 1983) . A significant proportion of the respiratory morbidity in term infants after caesarean is due to retention of fetal lung fluid (Milner 1978; Morrison 1995) . Administration of corticosteroids prior to elective section has been proposed based on the evidence that antenatal corticosteroids could help to facilitate the clearance of fluid from the fetal lung by increasing the number and function of sodium channels (Helve 2009; Jain 2006). The precise mechanism has not been confirmed and the long-term consequences of administration on child and adult health outcomes have not been established.
Why it is important to do this overview
Although the use of a single course of antenatal corticosteroids prior to preterm birth is generally accepted as one of the most effective interventions in perinatal medicine, there are several aspects of antenatal corticosteroid administration that remain uncertain, including:
• use of antenatal corticosteroids in late preterm gestations;
• use of antenatal corticosteroids at term gestations;
• use of repeat dose or doses of antenatal corticosteroids prior to preterm birth;
• optimal drug formulation, route and timing of administration;
• use of antenatal corticosteroids in different healthcare settings (low-, middle-and high-income countries). This overview will aim to clarify these uncertainties, identify the health benefits and potential harms associated with antenatal corticosteroid administration and identify areas which should be the focus of future high-quality randomised trials. Ultimately this overview will provide a user-friendly, one-stop source of current evidence from Cochrane systematic reviews for the use of antenatal corticosteroids and should encourage uptake and appropriate administration of antenatal corticosteroids to all eligible mothers and their babies.
O B J E C T I V E S
The objective is to summarise the available evidence from Cochrane systematic reviews for the effectiveness and safety of antenatal corticosteroid therapy to improve infant outcomes.
M E T H O D S Criteria for considering reviews for inclusion
Only published Cochrane systematic reviews, including full reviews, protocols and registered titles will be considered for inclusion in this overview. Where necessary and feasible we will update the relevant Cochrane reviews.
Participants
• Women who have received antenatal corticosteroids by any route prior to birth to promote fetal maturation.
Interventions
Antenatal corticosteroids administered by any route to women or to the fetus to promote fetal maturation (preterm/term). Comparisons will include the following.
• A single course of antenatal corticosteroids will be compared to placebo or no treatment
• Repeat course(s) of antenatal corticosteroids will be compared to no repeat course(s)
• Head-to-head comparisons of different types of antenatal corticosteroids (for example, dexamethasone versus betamethasone)
• One antenatal corticosteroid regimen compared to a different antenatal corticosteroid regimen (dose, frequency and timing, and route of administration)
Outcomes of interest
The following maternal, infant, child and child as an adult primary and secondary outcomes have been selected for this overview.
Maternal

Primary
• Maternal sepsis (however defined by study authors) • Systemic infection in the first 48 hours of life
Secondary
Child
Primary
• Survival free of any disability (however defined by study authors)
• Neurodevelopmental impairment (however defined by study authors)
Secondary
• Total deaths • Body size measurements (including z scores for weight, height, head circumference and body mass index (BMI))
• Asthma/wheeze • Risk factors for cardiovascular disease • Emotional and behavioural problems
Child as an adult
Primary
• Neurodevelopmental impairment at follow up (however defined by study authors)
• Survival free of cardio-metabolic disease
Secondary
• Growth measurements (including weight, head circumference, height, skin fold thickness and BMI)
• Age at puberty • Abnormal lung function (including z scores for forced expiratory volume in one second, forced vital capacity and forced expiratory flow at 25% to 75% of forced vital capacity)
• Health-related quality of life • Employment status
Search methods for identification of reviews
We will search the Cochrane Database of Systematic Reviews (The Cochrane Library) and Archie using the terms given in Appendix 1. We will not search any other sources.
Data collection and analysis
Selection of reviews
Two of the review authors will independently assess reviews that address the use of antenatal corticosteroids prior to:
• preterm birth for fetal maturation; or • prior to term birth for fetal lung maturation.
Any disagreements will be resolved by consensus or by a third review author. Where the Cochrane review search is out of date (search date is older than two years) and where feasible we will liaise with the Group to assess whether the review should be updated.
Data extraction and management
Two of the review authors (EM, JB, CM or DH) will independently extract data using an electronic form to be designed. We will resolve disagreements by consensus or by involving a third review author. We will extract and tabulate information as detailed. The overview will contain a 'Characteristics of included reviews' table. This table will include the following.
• The reference ID for each included review • The review title • The search date: when the review was last assessed as up-todate. Defined as: whether the date of the review is greater than two years. The two-year period starts from the date on which the review was assessed as being up-to-date
• The population demographics of each included review: including a summary of the participant characteristics (inclusion and exclusion criteria)
• The review characteristics: the number of trials in the review, number of women and infants
• The specific interventions assessed within each review • The control or comparisons interventions within each review
• The outcomes reported in each review • Any major limitations of the review.
We will prepare an 'Overview of reviews' table for each comparison by outcome (Becker 2011 Chapter 22 Cochrane Handbook, Figure 22.3b) and will include the following.
• A statistical summary of the treatment effects and 95% confidence intervals for the selected primary and secondary outcomes
• The number of studies and participants for whom data are available for each specific outcome and treatment comparison
• The quality of the evidence for the selected primary and secondary outcomes (we will report the quality of the evidence using the GRADEpro GDT software
Assessment of methodological quality of included reviews
Quality of evidence in included reviews
We will use the GRADEpro Guideline Development Tool ( GRADEpro GDT) to import data from Review Manager 5.3 (RevMan 2014) in order to create an 'Overview of reviews' table.
We will obtain the data for each of our primary and secondary outcomes from the included systematic reviews and enter them into GRADEpro GDT. We will appraise the quality of the evidence for each of the outcomes for:
• the risk of bias of included trials;
• directness of evidence;
• precision of the evidence; • heterogeneity;
• risk of publication bias (GRADE Handbook).
We will summarise the evidence for each of the selected clinical outcomes in an 'Overview of reviews' table which we will populate with the summary risk estimate and 95% confidence intervals. We will allocate a quality score for the strength of the clinical outcome evidence , ranging from HIGH to VERY LOW (as determined by GRADEpro GDT). The evidence can be downgraded from 'high quality' by one level for serious (or by two levels for very serious) limitations, depending on assessments for risk of bias, indirectness of evidence, serious inconsistency, imprecision of effect estimates or potential publication biases. The quality of the body of evidence relating to the following outcomes for the main comparisons (single course versus placebo/no treatment; repeat course(s) versus no repeat course(s) and headto-head comparisons of different types of antenatal corticosteroids (for example, dexamethasone versus betamethasone), and one antenatal corticosteroid regimen compared to a different antenatal corticosteroid regimen (dose, frequency and timing and route of administration) will be presented in separate tables. • Systemic infection in the first 48 hours of life
Child
• Total deaths
• Body size measurements (including z scores for weight, height, head circumference and body mass index (BMI))
• Asthma/wheeze • Risk factors for cardiovascular disease • Emotional and behavioural problems Child as an adult
• Survival free of cardio-metabolic disease • Growth measurements (including weight, head circumference, height, skin fold thickness and BMI)
Methodological quality of included reviews
We will also use AMSTAR (A MeaSurement Tool to Assess systematic Reviews) (Shea 2007) and ROBIS (Risk of Bias in Systematic Reviws) (Whiting 2014) to assess the quality of the included reviews by tabulating whether the following items have been adequately addressed.
• Prespecified question and inclusion criteria • Duplicate study selection and data extraction Two review authors will independently complete the assessment of methodological quality We will resolve any disagreements by consensus or by consulting a third review author. The review authors completing the assessment of quality will be independent of the included systematic review (not named as an author on the systematic review).
Data synthesis
For each comparison, we will give a narrative description of the summary statistics from the included reviews. We will present the results for the primary and secondary outcomes by the intervention (Becker 2011; Chapter 22 Cochrane Handbook, Figure 22.3b) , using tables and figures (e.g. characteristics of included reviews, overview of reviews tables, AMSTAR and ROBIS ratings for each systematic review). We will include other data, that may have been summarised in a narrative form, within the body of the text of the results.
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